Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03059446|
Recruitment Status : Enrolling by invitation
First Posted : February 23, 2017
Last Update Posted : May 2, 2018
|Condition or disease||Intervention/treatment||Phase|
|Nonalcoholic Steatohepatitis Liver Cirrhosis Non-alcoholic Fatty Liver Disease||Drug: Cenicriviroc||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)|
|Actual Study Start Date :||February 14, 2017|
|Estimated Primary Completion Date :||July 21, 2019|
|Estimated Study Completion Date :||October 31, 2019|
Cenicriviroc (CVC) 150 mg tablet once daily in the morning with food until CVC is commercially available or the study is terminated.
Cenicriviroc 150 mg tablet once daily in the morning with food.
Other Name: CVC
- Number of Participants with Treatment-emergent Adverse Events (AE) [ Time Frame: Day 1 until the drug is commercially available or the study is terminated (Approximately 2 Years) ]An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A treatment-emergent AE is an AE that occurs after a participant receives study drug.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03059446
Show 70 Study Locations
|Study Director:||Suzanne MacKinnon||Allergan|